Filtered By:
Condition: Hemorrhagic Stroke
Nutrition: Vitamins
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 553 results found since Jan 2013.
Time in therapeutic range of anticoagulation among patients with atrial fibrillation and cerebral amyloid angiopathy
Proc (Bayl Univ Med Cent). 2021 Dec 28;35(2):162-167. doi: 10.1080/08998280.2021.2013393. eCollection 2022.ABSTRACTAtrial fibrillation (AF) and cerebral amyloid angiopathy (CAA) present risks of ischemic stroke and intracerebral hemorrhage (ICH). Vitamin K antagonist use is associated with fluctuations in international normalized ratio (INR), which predispose to a higher bleeding risk. Patients with a diagnosis of AF and ICH while on a vitamin K antagonist were identified using the Rochester Epidemiology Project. Sixty patients were identified (mean age 81.3 years; 24 men). Thirty-three (55%) exhibited characteristics cons...
Source: Baylor University Medical Center Proceedings - March 9, 2022 Category: Universities & Medical Training Authors: Robert C Ward Jonathan Graff-Radford Shiva Ponamgi Stephen English Alayna Meskill Apurva B Challa David O Hodge Joshua P Slusser Alejandro A Rabinstein Samuel J Asirvatham David Holmes Christopher V DeSimone Source Type: research
Sex-Differences in Oral Anticoagulant-Related Intracerebral Hemorrhage
ConclusionSignificant sex-differences were observed in age, risk factors, access to treatment, and DNRs while no significant differences were observed in comorbidity burden, stroke severity, or hematoma volume. Outcomes, such as adjusted mortality, ability to walk, and neurological deterioration, were comparable. This study supports the presence of sex-differences in risk factors and care but not in presentation and outcomes.
Source: Frontiers in Neurology - March 3, 2022 Category: Neurology Source Type: research
NOAC Use Not Tied to ICH in Stroke Patients Treated With Alteplase
FRIDAY, Feb. 25, 2022 -- For patients with acute ischemic stroke receiving alteplase, use of non-vitamin K antagonist oral anticoagulants (NOACs) in the previous seven days is not associated with an increased risk for intracranial hemorrhage...
Source: Drugs.com - Pharma News - February 25, 2022 Category: Pharmaceuticals Source Type: news
Recent Use of NOACs and Intracranial Hemorrhage in Patients With Stroke Treated With Alteplase
This retrospective cohort study uses data from hospitals participating in the Get With The Guidelines –Stroke registry on patients with acute ischemic stroke and compares the safety and functional outcomes of intravenous alteplase among patients who were taking non–vitamin K antagonist oral anticoagulants (NOACs) prior to stroke vs patients who were not taking long-term anticoagulants.
Source: JAMA - February 22, 2022 Category: General Medicine Source Type: research
Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study
CONCLUSIONS: In the sample studied, half of the AF patients who suffered stroke/SE or major hemorrhagic episode had inadequate TTR and, despite this, after hospital discharge, they restarted treatment with VKA. These results highlight the need to evaluate safer and effective therapeutic alternatives in AF patients with poor TTR control after suffering a stroke/SE or major hemorrhagic episode.PMID:35120766 | DOI:10.1016/j.medcli.2021.12.004
Source: Medicina Clinica - February 5, 2022 Category: General Medicine Authors: Olga Gav ín Vanessa Rold án Pilar Llamas-Sillero Amparo Santamar ía Daniel Arum í Susana Fern ández de Cabo Source Type: research
